Resveratrol reduces the inflammatory activation of endothelum in patients with coronary heart disease combined with autoimmune thyroiditis

Ресвератрол снижает воспалительную активацию эндотелия у больных ишемической болезнью сердца в сочетании с аутоиммунным тиреоидитом
Natalia Chekalina 1
More Detail
1 Ukrainian Medical Stomatological Academy, Department of Internal Medicine, Poltava, Ukraine
J CLIN MED KAZ, Volume 3, Issue 41, pp. 21-26. https://doi.org/10.23950/1812-2892-2016-3-21-26
OPEN ACCESS 3096 Views 2341 Downloads
Download Full Text (PDF)

ABSTRACT

Objective: to study the effect of polyphenolic antioxidant resveratrol on markers of inflammatory activation of the endothelium (ET) in patients with stable coronary heart disease (CHD) in conjunction with autoimmune thyroiditis (AIT).
Methods. The  study  involved  30  patients  with  coronary  artery  disease:  stable  angina  pectoris,  FC  II  with  concomitant autoimmune thyroiditis, euthyroidism (study group), control group consisted of 20 healthy subjects. After 1 month of standard stabilizing therapy (β-blockers, statins, aspirin) for study group, in blood of participants was identified the levels of circulating endothelial  microparticles  (CEM)  CD32+CD40+  by  cytofluorometry,  after  which  for  study  group  additionally  was  appointed resveratrol at a dose of 100 mg per day and after 2 months we re-analyzed these indicators.
Results. In patients with stable coronary artery disease combined with AIT found increased amount of CEM CD32+CD40+. Under the influence of resveratrol in patients with CHD combined with AIT was revealed a significant reduction of the amount of CEM CD32+CD40+ in the peripheral blood, that can be the result of its effect on intracellular molecular cascades associated with nuclear transcription factor kappa B (NF-kB).
Conclusion. Resveratrol demonstrates the anti-inflammatory and protective action for endothelium: it reduces the indicator of inflammatory activation ET CEM CD32+CD40+ in the blood in patients with stable CHD combined with AIT.
Keywords: resveratrol, ischemic heart disease, autoimmune thyroiditis, chronic systemic inflammation, circulating endothelial microparticles

CITATION

Chekalina N. Resveratrol reduces the inflammatory activation of endothelum in patients with coronary heart disease combined with autoimmune thyroiditis. Journal of Clinical Medicine of Kazakhstan. 2016;3(41):21-6. https://doi.org/10.23950/1812-2892-2016-3-21-26

REFERENCES

  • Stres I hvorobi sistemi krovoobIgu (posIbnik) // Kovalenko V.M., Kornatskiy V.M. DU «NNTs «Institut kardIologI YiImenI akad. M.D.Strazheska», KiYiv. 2015. – S. 60-81.
  • Kravchenko V.I.., Postol S.V. DinamIka zahvoryuvanostI na patologIyu schitopodIbnoYi zalozi v UkraYinI // MIzhnarodniy endokrinologIchniy zhurnal. – 2011. – T. 35. - № 3. – S. 26-31.
  • Okayasu I. Transfer of experimental autoimmune thyroiditis to normal syngeneic mice by injection of mouse thyroglobulinsensitized T lymphocytes after activation with concanavalin A // Clin. Immunol. Immunopathol. – 1985. – Т. 36. – Р. 101–109.
  • Hasham A., Tome Y. Genetic and epigenetic mechanisms in thyroid autoimmunity // Immunology at Immunol. Research. – 2012. – Т. 54, № 1-3. – Р. 204-213.
  • Hedrick C.C. Lymphocytes in Atherosclerosis // Arterioscler. Thromb. Vasc. Biol. – 2015. –Т. 35. - № 2. – Р. 253–257.
  • Baur J.A., Sinclair D.A. Therapeutic potential of resveratrol: the in vivo evidence // Nat. Rev. Drug Discov. – 2006. – Т. 5. - № 6. – Р. 493–506.
  • Petersa A.L., Stunzb L.L., Bishopa G.A. CD40 and autoimmunity: The dark side of a great activator // Seminars in Immunology. – 2009. – Т. 21. - № 5. – Р. 293–300.
  • Meziani F., Tesse A., Andriantsitohaina R. Microparticles are vectors of paradoxical information in vascular cells including the endothelium: role in health and diseases // Pharmacol. Rep. – 2008. – Т. 60. - № 1. – Р. 75-84.
  • Distler J.H., Jüngel A., Huber L.C. et al. The induction of matrix metalloproteinase and cytokine expression in synovial fibroblasts stimulated with immune cell microparticles // Proc. Nat. Acad. Sci. USA. – 2005. – Т. 102. - № 8. – Р. 2892-2897.
  • Chironi G.N., Boulanger C.M., Simon A., Dignat-George F., Freyssinet J.M., Tedgui A. Endothelial microparticles in diseases // Cell. Tissue Res. – 2009. – Т. 335. - № 1. – Р. 143-151.
  • Montalescot G., Sechtem U., Achenbach S. et al. 2013 ESC guidelines on the management of stable coronary artery disease // European Heart Journal. – 2013. – Т. 34. - № 38. – Р. 2949–3003.
  • Standarti dIagnostiki ta lIkuvannya endokrinnih zahvoryuvan (dovIdnik) // Tronko M.D. TOV «Doktor-MedIa». KiYiv. 2007. – S. 48-53.2 №3 (41) 2016 Clinical Medicine of Kazakhstan 
  • Kutsenko N.L., Savchenko L.G., Kaydasheva E.I. i dr. Opredelenie soderzhaniya tsirkuliruyuschih CD32 CD40 - mikrochastits — modifikatsiya metoda otsenki destruktsii endotelialnyih kletok // Klin. lab. dIagnostika. - 2011. - № 7. – S. 20-23.
  • ChekalIna N.I. Pokazniki endotelIalnoYi disfunktsIYi u hvorih na autoImunniy tireoYidit u spoluchennI z IshemIchnoyu hvoroboyu sertsya // Zhurnal klInIchnih ta eksperimentalnih medichnih doslIdzhen. – 2016. – T. 4. - № 2. – S. 293–302.
  • ChekalIna N.I., Kazakov Yu.M., Burmak Yu.G. i dr. DIagnostika endotelIalnoYi disfunktsIYi u hvorih na autoImunniy tireoYidit za nayavnostI aterosklerotichnogo urazhennya sudin // VseukraYinska nauk.-prakt. konf. z mIzhnar. uchastyu «AktualnI pitannya dIagnostiki, lIkuvannya, ratsIonalnoYi farmakoterapIYi, dispanserizatsIYi ta reabIlItatsIYi v praktitsI sImeynogo lIkarya» 12-13 travnya 2016 r. - TernopIl. 2016. – S. 144.
  • Tanigaki K., Sundgren N., Khera A., et al. Fcγ Receptors and Ligands and Cardiovascular Disease // Circ Res. – 2015. – Т. 116. - № 2. – Р. 368–384.
  • Ridker P.M. From C-Reactive рrotein to interleukin-6 to іnterleukin-1: moving upstream to identify novel targets for atheroprotection // Circ. Res. – 2016. – Т. 118. - № 1. – Р. 145-156.
  • Pan L., Kreisle R.A., Shi Y. Expression of endothelial cell IgG Fc receptors and markers on various cultures // Chin. Med. J. (Engl). – 1999. – Т. 112. - № 2. – Р. 157-161.
  • Wagner A.H., Gebauer M., Pollok-Kopp B., Hecker M. Cytokine-inducible CD40 expression in human endothelial cells is mediated by interferon regulatory factor-1 // Blood. – 2002. – Т. 99. - № 2. – Р. 520-525.
  • Kawabe T., Matsushima M., Hashimoto N., et al. CD40/CD40 ligand interactions in immune responses and pulmonary immunity // Nagoya J. Med. Sci. – 2011. – Т. 73. - № 3-4. – С. 69–78.
  • Dongari-Bagtzoglou A.I., Thienel U., Yellin M.J. CD40 ligation triggers COX-2 expression in endothelial cells: evidence that CD40-mediated IL-6 synthesis is COX-2-dependent // Inflamm Res. – 2003. – Т. 52. - № 1. – Р. 18-25.
  • Ren Z., Wang L., Cui J., et al. Resveratrol inhibits NF-kB signaling through suppression of p65 and IkappaB kinase activities // Pharmazie. – 2013. – Т. 68. - № 8. – Р. 689-694.
  • Knight R.A., Scarabelli T.M., Stephanou A. STAT transcription in the ischemic heart // JAKSTAT. – 2012. – Т. 1. - № 2. – Р. 111–117.
  • Kaydashev I.P. Sistema sirtuinov i vozmozhnosti regulirovaniya eYo sostoyaniya v klinicheskoy praktike (obzor literaturyi) // Zhurnal NAMN Ukrainyi 2012. – T. 18. - № 4. – R. 418-429.
  • Price N.L., Gomes A.P., Alvin J.Y. et al. SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function // Cell Metabolism. – 2012. – Т. 15. - № 5. – Р. 675–690.